Sofituzumab Vedotin Anti-MUC15 ADC (RG7458 / DMUC5754A) Clinical Trials

TrialTitleStudy Record DetailPhaseSponsor/Collaborator
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic CancerNCT01335958Phase IGenentech, Inc./Roche

Sofituzumab Vedotin is an Anti-MUC15 antibody-drug conjugate also known as RG7458 or DMUC5754A.

Last Editorial Review: August 12, 2015